haemophilia a
Roche candidate shows early promise for treating haemophilia A
June 25, 2025Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment
June 19, 2024Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi
Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …
Sanofi shares data about new drug for haemophilia A in paediatric patients
June 26, 2023Research and Development Haematology, Sanofi, clinical trial, haemophilia a
Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …
NHS Scotland gives green light to funding haemophilia A drug Hemlibra
December 18, 2019Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland
NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …
Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy
December 17, 2019Manufacturing and Production haemophilia, haemophilia B, haemophilia a
The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, …
Shire scores European approval for Adynovi in haemophilia A
January 15, 2018Sales and Marketing Adynovi, Europe, European Commission, Shire, haemophilia, haemophilia a, pharma
Shire has revealed that the European Commission has approved Adynovi (antihaemophilic factor (recombinant), PEGylated) for on-demand and prophylactic use in …
Strong early data on haemophilia gene therapy boosts Biomarin
July 28, 2016Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a
Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …
FDA approves CSL haemophilia A drug
May 26, 2016Sales and Marketing CSL, afstyla, haemophilia a, treatment
CSL (ASX: CSL) has announced that the US Food and Drug Administration (FDA) has approved Afstyla (antihaemophilic factor [recombinant), single …
FDA approves Bayer haemophilia A drug Kovaltry
March 17, 2016Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound
Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …
Europe approves Bayer haemophilia drug
February 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, haemophilia a
Bayer has received approval from the European Commission for its haemophilia A drug Kovaltry (octocog alfa) in patients of all …
Sobi launches new haemophilia treatment in UK
January 19, 2016Manufacturing and Production, Sales and Marketing elocta, haemophilia a, sobi
Swedish Orphan Biovitrum Ltd (Sobi) has launched its haemophilia A treatment Elocta (efmoroctocog alfa) in the UK, following its EU …
Sobi and Biogen’s haemophilia A treatment EU-approved
November 27, 2015Sales and Marketing Biogen, elocta, haemophilia a, sobi
Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …
Genentech Haemophilia therapy gets FDA breakthrough designation
September 4, 2015Research and Development, Sales and Marketing Genentech, Roche, haemophilia a
Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
Bayer files haemophilia drug in EU
December 5, 2014Sales and Marketing BAY 81-8973, Bayer, Biogen IDEC, EMA, elocta, haemophilia a, kogenate
Bayer has submitted a marketing authorisation application to the EMA for its haemophilia A therapy BAY 81-8973. The German firm’s …
EMA review for Biogen Idec’s haemophilia A therapy
November 4, 2014Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi
The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …
